ACP
ELDN icon

Acuta Capital Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Acuta Capital Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-235,750
Closed -$971K – 38
2024
Q4 		$971K Buy
+235,750
New +$929K 0.98% 27

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Acuta Capital Partners's ELDN Position: Q1 2025 in Review

Acuta Capital Partners sold out of Eledon Pharmaceuticals (ELDN) in Q1 2025, closing a stake of 235,750 shares — an estimated $971K sold.

Acuta Capital Partners first reported a position in ELDN in Q4 2024 and held it in 1 quarter. The position peaked at $971K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q1 2025.

  • Acuta Capital Partners reported no remaining Eledon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 235,750 Eledon Pharmaceuticals shares in Q1 2025, an estimated $971K.
  • Acuta Capital Partners first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Acuta Capital Partners's Eledon Pharmaceuticals position peaked at $971K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2025.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.